成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Nepafenac

Nepafenac Struktur
78281-72-8
CAS-Nr.
78281-72-8
Englisch Name:
Nepafenac
Synonyma:
Nevanac;CS-328;AL 6515;AHR 9434;Nepafenac;Nepafanac;Nepafenac>Nepafenac API;NEPAFENAC STD;Nepafenac - WS
CBNumber:
CB01116872
Summenformel:
C15H14N2O2
Molgewicht:
254.28
MOL-Datei:
78281-72-8.mol

Nepafenac Eigenschaften

Schmelzpunkt:
177-181°C
Siedepunkt:
562.5±50.0 °C(Predicted)
Dichte
1.249±0.06 g/cm3(Predicted)
storage temp. 
room temp
L?slichkeit
DMSO: ≥5mg/mL
pka
16.09±0.40(Predicted)
Aggregatzustand
powder
Farbe
faint yellow to dark yellow
Wasserl?slichkeit
0.014 mg/mL in water
Merck 
14,6469
InChI
InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
InChIKey
QEFAQIPZVLVERP-UHFFFAOYSA-N
SMILES
C1(CC(N)=O)=CC=CC(C(=O)C2=CC=CC=C2)=C1N
CAS Datenbank
78281-72-8(CAS DataBase Reference)
Sicherheit
  • Risiko- und Sicherheitserkl?rung
  • Gefahreninformationscode (GHS)
Kennzeichnung gef?hrlicher N
R-S?tze: 50/53
S-S?tze: 60-61
RIDADR  UN 3077 9 / PGIII
WGK Germany  3
RTECS-Nr. CY1480710
HS Code  2924.29.6250
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H400 Sehr giftig für Wasserorganismen. Kurzfristig (akut) gew?ssergef?hrdend Kategorie 1 Warnung GHS hazard pictogramssrc="/GHS09.jpg" width="20" height="20" /> P273, P391, P501
Sicherheit
P273 Freisetzung in die Umwelt vermeiden.
P391 Verschüttete Mengen aufnehmen.
P501 Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Nepafenac Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Nepafenac, launched by Alcon Laboratories, is a topical ophthalmic medication indicated for the treatment of ocular pain and inflammation associated with cataract surgery. Nepafenac is a prodrug of amfenac, which is an NSAID and a potent non-selective inhibitor of COX-1 (IC50=0.25 μM)) and COX-2 (IC50=0.15μM). Nepefenac itself exhibits only weak activity against COX-1 (IC50=64.3μM). Amfenac (Fenazox) has been marketed in Japan since 1986 for the treatment of rheumatoid arthritis, post-surgical pain, and inflammation. With most NSAIDs that are currently being used as topical ophthalmic agents, the maximum drug concentration is achieved on the ocular surface, with progressively lower concentrations in the cornea, aqueous humor, vitreous, and retina. Nepafenac has been found to have a penetration coefficient that is 4-28 times greater than that achieved with conventional NSAIDs such as diclofenac, bromofenac, and ketorolac. In addition, the bioconversion of nepefenac to amfenac is primarily mediated by ocular tissue hydrolases, specifically in the iris, ciliary body, retina, and choroid. The enhanced permeability of nepefenac combined with rapid bioactivation in the ocular tissue translates into superior anti-inflammatory efficacy at the target sites.

Chemische Eigenschaften

Nepafenac is a light Yellow Solid or powder. It is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF).

Verwenden

Nepafenac is a non-steroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop. It reduces pain and inflammation in the eyes. Nepafenac ophthalmic is used to reduce pain and swelling after cataract surgery.

Definition

ChEBI: Nepafenac is a monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. It has a role as a prodrug, a cyclooxygenase 2 inhibitor, a cyclooxygenase 1 inhibitor, a non-steroidal anti-inflammatory drug and a non-narcotic analgesic.

Clinical Use

Nepafenac is a novel ophthalmic non-steroidal anti-inflammatory drug (NSAID), for the treatment of eye pain and inflammation caused by cataract surgery, compared with traditional NSAIDs, chemical structure of Nepafenac is conducive to make it rapidly penetrate the cornea and distribute to its target site, which is helpful to reduce the accumulation of the drug in the corneal surface and to reduce the incidence of complications of the eye surface, it has many advantages such as infiltration, targeting strong, little toxic side effects and so on.
August 19, 2005 ,the US Food and Drug Administration (FDA) approved nepafenac ophthalmic suspension for the treatment of cataract surgery-related pain and inflammation, it is the first ophthalmic NSAID prodrug formulation approved for marketing.
Nepafenac after ocular administration, can rapidly pass through the cornea , and under the action of eye tissue hydrolytic enzymes,it can become into ammonia diclofenac (a kind of NSAID); and ammonia diclofenac by inhibiting prostaglandin H synthase ( cyclooxygenase), can block prostaglandin synthesis to play its role as an anti-inflammatory analgesic. As is known, prostaglandin is one of the media causing ocular inflammation it can lead to blood-aqueous barrier crash, vasodilatation, increased vascular permeability and leukocyte chemotaxis, etc. In addition, prostaglandins can also control contraction of the iris sphincter through non-cholinergic mechanism which can trigger the miosis reaction during eye surgery and after surgery. After ocular administration of NSAIDs, it can inhibit prostaglandins synthesis in the iris, ciliary body and conjunctiva, so people can prevent eye inflammation, and reduce the associated pain.
The above information is edited by the chemicalbook of Tian Ye.

Mode of action

Nepafenac is a non-steroidal anti-inflammatory and analgesic prodrug. After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a nonsteroidal anti-inflammatory drug. Amfenac inhibits the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.

Nepafenac Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Nepafenac Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 368)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shandong Hengshannuode Pharmaceutical Technology Co., Ltd.
+8615065888978
admin@hsnordpharma.com China 92 58
Tianjin Kilo Pharmaceutical Sci-Tech Co., Ltd
+86-02223869539 +86-15560057295
trade.kilopharma@foxmail.com China 27 58
Sinoway Industrial co., ltd.
0592-5800732; +8613806035118
xie@china-sinoway.com China 988 58
Hebei Fengjia New Material Co., Ltd
+86-0311-87836622 +86-17333973358
sales06@hbduling.cn China 8051 58
Anhui Ruihan Technology Co., Ltd
+8617756083858
daisy@anhuiruihan.com China 973 58
Hebei Zhuanglai Chemical Trading Co Ltd
+86-16264648883 +86-16264648883
niki@zlchemi.com China 2986 58
Capot Chemical Co.,Ltd.
+86-(0)57185586718 +86-13336195806
sales@capot.com China 29791 60
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21634 55
Hangzhou FandaChem Co.,Ltd.
+8615858145714
FandaChem@Gmail.com China 9080 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070
product@chemlin.com.cn CHINA 3009 60

78281-72-8()Verwandte Suche:


  • AHR 9434
  • AL 6515
  • Nepafenac
  • 2-(2-amino-3-benzoyl-phenyl)acetamide
  • 2-Amino-3-benzoylbenzeneacetamide
  • Nepafenac - WS
  • nepafenac,Nevance
  • Nepafanac
  • (R)-(but-3-yn-2-yloxy)trimethylsilane
  • Nepafenac, 99%, a selective COX-2 inhibitor
  • CS-328
  • Nepafenac>
  • Benzeneacetamide, 2-amino-3-benzoyl-
  • Nepafenac USP/EP/BP
  • Nepafenac API
  • Nepafenac (AHR9434
  • NepafenacQ: What is Nepafenac Q: What is the CAS Number of Nepafenac Q: What is the storage condition of Nepafenac Q: What are the applications of Nepafenac
  • Nevanac
  • Nepafenac/AHR9434/AL6515/Nevanac
  • NEPAFENAC STD
  • Nepafenac (200 mg)
  • 78281-72-8
  • 8281-72-8
  • C15H9D5N2O2
  • Nevanac
  • Other APIs
  • Amines
  • Aromatics
  • Intermediates & Fine Chemicals
  • Isotope Labelled Compounds
  • Pharmaceutical intermediate
  • Pharmaceuticals
  • API
Copyright 2019 ? ChemicalBook. All rights reserved